Array BioPharma Appoints April H. Teitelbaum, MD, MS, FACP Vice President of Clinical Development - Oncology

    BOULDER, Colo., Oct. 5 /PRNewswire-FirstCall/ -- Array BioPharma Inc.
 (Nasdaq:   ARRY) today announced the appointment of April H. Teitelbaum, MD,
 MS, FACP, to the newly created position of Vice President of Clinical
 Development - Oncology, effective October 4, 2006. Dr. Teitelbaum will
 oversee the medical strategy and clinical development of Array's oncology
 drug pipeline and will report to the company's Chief Executive Officer,
 Robert E. Conway.
     "April's solid track record and experience in developing new cancer
 drugs will be invaluable to Array as we advance our extensive drug
 pipeline," said Mr. Conway. "April's expertise in running complex clinical
 trials will be a competitive advantage for Array as we are on track for
 having five drugs in clinical development by the end of 2006."
     Over the last 16 years, Dr. Teitelbaum has held positions of increasing
 responsibility for clinical and strategic development of oncology
 therapeutics at several pharmaceutical and biotechnology companies
 including Amgen, Sequus Pharmaceuticals, Ligand, the Johnson and Johnson
 family of companies, and Kyowa Pharmaceuticals, Inc. She has been involved
 in clinical development, including registration strategies and expansion of
 label, for multiple oncology therapeutics including Neupogen, Doxil (for
 the treatment of relapsed ovarian cancer and multiple myeloma), and
 Yondelis, which is currently in clinical trials for the treatment of
 recurrent soft tissue sarcoma as well as other malignancies. Dr. Teitelbaum
 also headed her own consulting company and has served as a consultant to
 several companies for development of novel oncology therapeutics. Before
 embarking on a career in pharmaceutical drug development, Dr. Teitelbaum
 was engaged in private practice, specializing in Hematology and Medical
 Oncology. While in practice, she served as an Investigator for several
 clinical trials and maintained academic appointments through both UCLA and
 USC.
     Dr. Teitelbaum received her M.D. from Rush Medical College and an M.S.
 degree in erythropoietin physiology from New York University. She completed
 subspecialty training in both Hematology and Medical Oncology at USC
 Medical Center and UCLA School of Medicine and is a diplomat of the
 American Board of Internal Medicine, Hematology, and Medical Oncology.
     About Array BioPharma:
     Array BioPharma Inc. is a biopharmaceutical company focused on the
 discovery, development and commercialization of targeted small molecule
 drugs to treat life threatening and debilitating diseases. Our proprietary
 drug development pipeline is focused on the treatment of cancer and
 inflammatory disease and includes clinical candidates that are designed to
 regulate therapeutically important targets. In addition, leading
 pharmaceutical and biotechnology companies collaborate with Array to
 discover and develop drug candidates across a broad range of therapeutic
 areas. For more information on Array, please go to www.arraybiopharma.com.
     Array BioPharma Forward-Looking Statement:
     This press release contains forward-looking statements within the
 meaning of the Private Securities Litigation Reform Act of 1995 that
 involve significant risks and uncertainties, including those discussed in
 our annual report filed on form 10-K for the year ended June 30, 2006, and
 in other reports filed by Array with the Securities and Exchange
 Commission. Because these statements reflect our current expectations
 concerning future events, our actual results could differ materially from
 those anticipated in these forward-looking statements as a result of many
 factors. These factors include, but are not limited to, our ability to
 continue to fund and successfully progress internal research efforts and to
 create effective, commercially viable drugs, our ability to achieve and
 maintain profitability, the extent to which the pharmaceutical and
 biotechnology industries are willing to in-license drug candidates for
 their product pipelines and to collaborate with and fund third parties for
 their drug discovery activities, our ability to out-license our proprietary
 candidates on favorable terms, risks associated with our dependence on our
 collaborators for the clinical development and commercialization of our
 out-licensed drug candidates, the ability of our collaborators and of Array
 to meet drug objectives, including clinical trials, tied to milestones and
 royalties, and our ability to attract and retain experienced scientists and
 management. We are providing this information as of October 5, 2006. We
 undertake no duty to update any forward-looking statements to reflect the
 occurrence of events or circumstances after the date of such statements or
 of anticipated or unanticipated events that alter any assumptions
 underlying such statements.
 
 

SOURCE Array BioPharma Inc.